Publications by authors named "Mahesh Kumar Balasundaram"
Background: Peripheral neuropathy is four times more common in geriatric age group patients compared to younger ones. Most of the trials have targeted adult population, and there is scarcity of data in the geriatric age group.
Purpose: A real-world study was planned on geriatric patients suffering from peripheral neuropathy to analyse the effectiveness and safety of first-line drugs used in the management of peripheral neuropathy.
Trofinetide in Rett syndrome: A brief review of safety and efficacy.
Intractable Rare Dis Res
November 2023
Article Synopsis
- * There is no cure for RTT, but symptoms can be managed with therapy; Trofinetide, initially developed for stroke, has shown positive results in Phase II clinical trials for RTT.
- * Recently, Trofinetide received FDA approval and orphan drug designation as the first approved treatment for RTT, demonstrating safety and effectiveness without known drug interactions.
Background: Recently, the United States Food and Drug Administration (USFDA) approved viloxazine extended-release (ER) to manage attention-deficit hyperactivity disorder (ADHD) in pediatric patients of 6-17 years of age.
Objective: To perform a meta-analysis to determine the safety and efficacy of viloxazine ER in the management of ADHD.
Data Source And Methods: A literature search was performed through the databases Cochrane Library, PubMed, and clinicaltrials.
Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.
Clin Drug Investig
April 2022
Background And Objective: Atogepant is the latest calcitonin gene-related peptide (CGRP) antagonist approved exclusively for prophylaxis of episodic migraine and is administered orally in doses of 10-60 mg/day. This article aims to provide a systematic review of the efficacy and safety of atogepant in migraine prevention.
Methods: The literature was searched in different databases, i.